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Introduction
Japanese encephalitis virus (JEV) is a mosquito-borne member of 
the Flaviviridae family and is a leading cause of viral encephali-
tis in Asia. The first generation of prophylactic vaccines against 
JEV employed virus derived from the brains of infected mice 
a randomized, double-blind, study was conducted to evaluate the safety, tolerability and immunogenicity of a live 
attenuated Japanese encephalitis chimeric virus vaccine (Je-cV) co-administered with live attenuated yellow fever  (YF) 
vaccine (YF-17D strain; stamaril®, sanofi pasteur) or administered sequentially.
participants (n = 108) were randomized to receive: YF followed by Je-cV 30 days later, Je followed by YF 30 days later, 
or the co-administration of Je and YF followed or preceded by placebo 30 days later or earlier. placebo was used in a 
double-dummy fashion to ensure masking. Neutralizing antibody titers against Je-cV, YF-17D and selected wild-type Je 
virus strains was determined using a 50% serum-dilution plaque reduction neutralization test (pRNT50). seroconversion 
was defined as the appearance of a neutralizing antibody titer above the assay cut-off post-immunization when not pres-
ent pre-injection at day 0, or a least a four-fold rise in neutralizing antibody titer measured before the pre-injection day 
0 and later post vaccination samples.
There were no serious adverse events. Most adverse events (aes) after Je vaccination were mild to moderate in inten-
sity, and similar to those reported following YF vaccination. seroconversion to Je-cV was 100% and 91% in the Je/YF and 
YF/Je sequential vaccination groups, respectively, compared with 96% in the co-administration group. all participants 
seroconverted to YF vaccine and retained neutralizing titers above the assay cut-off at month six. Neutralizing antibodies 
against Je vaccine were detected in 82–100% of participants at month six. These results suggest that both vaccines may 
be successfully co-administered simultaneously or 30 days apart.
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and inactivated with formalin.1,2 These vaccines provide very 
effective short term immunity3-5 however associated rare adverse 
events1,6-8 and uncertainty as to the duration of protection against 
infection9 are matters of concern. To overcome these concerns 
a live attenuated Japanese encephalitis chimeric virus vaccine 
(JE-CV) also known as Acambis’s ChimeriVax®-JE has been 
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six treatment groups were well matched with respect to demo-
graphic characteristics (data not shown).
Reactogenicity and safety. There were no deaths or serious 
AEs during the study and no participant withdrew from the 
study because of an AE. Systemic AEs occurring 30 days after the 
first immunization on day 0 for each treatment group was similar 
(97–100% of subjects experienced a systemic AE). The incidence 
of AEs was higher after the first immunization than the second 
(92% vs. 79%) for all participants. Fatigue and malaise were the 
most commonly reported treatment related, systemic AEs, and 
were typically mild to moderate in intensity (Table 1). There 
were four severe systemic AEs reported by three participants; 
three of these occurred in two participants following immuni-
zation with YF vaccine and the last in a placebo recipient. One 
developed by removing pre-membrane and enve-
lope coding sequences from the yellow fever vac-
cine virus (strain 17D) and replacing them with the 
corresponding sequences from the attenuated JEV 
strain, SA14-14-2.10,11
There is a possibility YF-17D vaccine and 
JE-CV could interact as they share antigenic deter-
minants and prior immunization with one might 
boost or suppress immune responses to the other. 
Furthermore, JE-CV as a chimeric vaccine shares 
non-structural coding sequences from the YF-17D 
vaccine so prior vaccination with YF vaccines could 
similarly boost or suppress immune responses and 
visa versa. Monath et al.11 found no significant dif-
ference between the anti-JE-CV neutralizing anti-
body responses in JE-CV vaccinated participants 
with and without a history of YF immunization. 
However a subsequent small-scale study suggested 
that immunization with JE-CV 30 days prior to 
YF vaccine resulted in a reduced rate of yellow fever 
virus (YFV) seroconversion (64% compared with 
91%) and lower titers.12 Neither of these observed 
differences was statistically significant (p > 0.05) 
but warranted further clinical investigation given 
the possibility that a military or travelling popu-
lation would use both vaccines concurrently or in 
close proximity.
We report a study designed to further assess 
the safety profile of JE-CV administered concomi-
tantly or one month before or after YF vaccine, 
and to assess the immune response elicited by con-
comitant administration of JE and YF vaccines. 
We also assessed the persistence of neutralizing 
antibody responses six months after vaccination. 
Finally we explored whether JE-CV vaccine-
induced antibodies are able to neutralize a panel 
of wild-type JEV strains, representative of the four 
main genotypes.
Results
Study population. Of the 137 screened volunteers, 
108 participants were enrolled, and randomized per 
protocol, 106 of whom completed the study to day 60 (Fig. 1). 
Mean participant age was 26 years (range 18 to 53 years) with 
a 57/43% male to female ratio. Mean weight was 72 kg, (range 
42–117 kg) and 92% of participants were Caucasian. More than 
a third (34/108) of participants was excluded retrospectively from 
the per-protocol (PP) population because neutralizing flavivirus 
antibody titers to one or more flaviviruses were detected in their 
baseline serum sample by 50% serum-dilution plaque reduc-
tion neutralization test. These flaviviruses included Alfuy virus 
(n = three), dengue virus serotype one, two and four (n = 21, nine 
and two, respectively), JEV (n = three), Murray valley encephali-
tis virus (n = three) and YFV (n = four). Despite the high preva-
lence of flaviviruses antibodies across the study population; the 
Figure 1. study disposition.
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participant in the YF/JE group reported severe fatigue and head-
ache that developed five and seven days, respectively following 
YF vaccination. Both events resolved within three days and were 
deemed probably related to treatment.
Local reactogenicity. Within 30 days after the first injection, 
pain and erythema were the most commonly reported treat-
ment related, local AEs and occurred at comparable rates in all 
groups, i.e., were comparable when either vaccine or placebo 
was administered separately, or when vaccines were co-admin-
istered (Table 1). Four participants had local adverse events of 
moderate severity, while all other participants described local 
reactions of mild severity. There were no severe local adverse 
events. Observations after the second injection were compa-
rable with those after the first, but with lower reaction rates 
(data not shown).
Laboratory parameters. Mean values for blood biochemistry 
and haematology variables were similar in each treatment group 
at screening and there were no apparent changes in any of the 
mean variables from screening to days 15 and 30, or from day 30 
(prior to immunization with the second vaccine) to days 45 and 
60 [data not shown]. There was no significant difference between 
treatment groups in the incidence or magnitude of out of range 
hematology, biochemistry or urinalysis results. The most com-
monly observed haematology shifts were increases or decreases in 
neutrophils and eosinophils.
Forty one participants had creatinine phosphokinase (CPK) 
values that met protocol defined mild toxicity grading during 
the follow-up (>237 units Unit(s) [U]/L for females and >255 
U/L for males). Creatinine phosphokinase was monitored dur-
ing the study as part of the chemistry panel but these findings 
prompted further investigation to determine whether they were 
treatment related. No concomitant abnormal elevation for the 
cardiac CPK isoenzyme was observed in these participants. Prior 
to any immunization two and nine participants reached moder-
ate (≥400 to <1,000 U/L) and mild (255 to <400 U/L males and 
255 to <400 U/L females) CPK levels, respectively, at screening. 
CPK monitoring continued throughout the treatment phase at 
day 15 (seven participants), day 30 (10 participants), day 45 (four 
participants) and at day 60 (eight participants) reached mild to 
moderate CPK levels. The single elevated CPK value that reached 
severe toxicity at day 60 was in a participant in the YF/JE group, 
30 days after immunization with JE-CV. The parameter resolved 
Table 1. Treatment-related adverse events reported by two or more participants during the thirty days following first administration, on Day 0 of Je-
cV or YF-17D alone, or the co administration of Je-cV and YF-17D, or placebo
Group and vaccines received at first dose on Day 0
JE/YF group YF/JE group Co-administration
All participantsSystem organ class 
 preferred term
(JE-CV + placebo) (YF-17D + placebo) JE-CV + YF-17D Placebo + placebo
Number of subjects n = 36 n = 36 n = 18 n = 18 n = 108
n (%) n (%) n (%) n (%) n (%)
General 23 (64) 20 (56) 7 (39) 10 (56) 60 (56)
Fatigue 16 (44) 15 (42) 3 (17) 10 (56) 44 (41)
Malaise 10 (28) 12 (33) 2 (11) 6 (33) 30 (28)
pyrexia 3 (8) 4 (11) 0 (-) 3 (17) 10 (9)
chills 1 (3) 4 (11) 1 (6) 2 (11) 8 (7)
Injection site
Injection site pain 10 (28) 6 (17) 4 (22) 2 (11) 22 (20)
Injection site erythema 4 (11) 3 (8) 1 (6) 1 (11) 9 (8)
Injection site swelling 4 (11) 0 (-) 2 (11) 1 (6) 7 (7)
Injection site hemorrhage 1 (3) 1 (3) 0 (-) 0 (-) 2 (2)
Nervous System 18 (50) 20 (56) 6 (33) 8 (44) 52 (48)
Headache 18 (50) 20 (56) 6 (33) 8 (44) 52 (48)
Dizziness 0 (-) 2 (6) 0 (-) 0 (-) 2 (2)
Musculoskeletal 7 (19) 12 (33) 3 (17) 5 (28) 27 (25)
Myalgia 7 (19) 12 (33) 3 (17) 4 (22) 26 (24)
Gastrointestinal 11 (31) 7 (19) 2 (11) 6 (33) 26 (24)
abdominal pain 5 (14) 4 (11) 2 (11) 3 (17) 14 (13)
Diarrhea 7 (19) 2 (6) 2 (11) 3 (17) 14 (13)
Nausea 3 (8) 1 (3) 1 (6) 2 (11) 7 (7)
Respiratory, Thoracic, 
Mediastinal
0 (-) 5 (14) 0 (-) 1 (6) 6 (6)
pharyngolaryngeal pain 0 (-) 2 (6) 0 (-) 1 (6) 3 (3)
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Discussion
We found no evidence that immunization with YF vaccine 
together with, prior to or after immunization with JE vaccine 
resulted in any increase in the rate of AEs compared to that asso-
ciated with JE-CV alone. Adverse events were similar to those 
experienced in previous JE-CV trials.11,12 Fatigue and malaise 
were the most commonly reported treatment-related systemic 
AEs while injection site pain and erythema were the most com-
monly observed, local AEs.
The most commonly reported laboratory abnormality was 
elevated levels of CPK which may have been due to physical exer-
cise-induced muscle injury.13 The study participants were pre-
dominately physically active adults and there was no requirement 
for participants to reduce levels of exercise prior to immunization 
or follow-up blood sampling. These abnormal CPK values were 
detected at screening, were transient and self-limiting, and were 
not associated with any particular treatment group or local AE. It 
is unlikely, therefore, that these elevations in CPK were related to 
immunization. Other haematology, urinalysis and liver enzyme 
values outside the normal range were minor and unrelated to 
clinical syndromes. The tolerability and safety of JE-CV there-
fore is consistent with the available safety data for JE-CV and the 
safety profile of YF-17D.
Monath et al.12 previously reported a reduction in the number 
of participants seroconverting to YF vaccine (64%) when partici-
pants were immunized with JE-CV 30 days prior to YF vaccine. In 
contrast, 91% of JE-CV naïve participants in this study serocon-
verted to YF vaccine. The magnitude of the anti-YFV neutralizing 
response (log neutralization index) was also lower in participants 
who had received JE-CV 30 days prior (1.59, standard deviation 
[SD] = 1.47) compared to JE-CV naïve subjects (2.29, SD = 1.03). 
In our study, all participants seroconverted to YFV and there were 
no statistically significant differences in anti-YFV GMTs between 
any of the treatment groups. The differing results for our study 
and those of Monath et al.11,12 are difficult to assess due to the 
small sample sizes. YF-VAX® has approximately 5 log
10
 PFU 
of YF-17D virus and is stabilized with sorbitol and hydrolyzed 
to mild toxicity, unrelated to immunization, four days later. 
Retrospective questioning of the participant revealed that he had 
undertaken mountain climbing before testing at day 60. For the 
remaining participants, all other reported mild to moderate CPK 
values resolved spontaneously.
Immunogenicity. All participants in the JE/YF group and 
91% of participants in the YF/JE group seroconverted to JE-CV, 
30 days after JE vaccination. When co-administered with YF 
vaccine, 96% of participants seroconverted to JE-CV within 30 
days of vaccination. Two participants in the YF/JE group had 
detectable neutralizing antibodies (PRNT
50
 >1:20) to JE-CV 
prior to JE vaccination, and did not demonstrate a four-fold rise 
in titer post immunization. One participant in the co-adminis-
tration group did not seroconvert to JE-CV (Table 2).
The neutralizing geometric mean titers (GMTs) for anti-JE-
CV antibodies are shown in Figure 2. The anti-JE-CV GMT for 
the JE/YF group was significantly higher than that for the YF/
JE group (ratio of means 0.3, 95% CI 0.1, 0.9). When JE and YF 
vaccines were co-administered, the anti-JE-CV titer at day 30 
also was significantly lower than that for the JE/YF participants 
(ratio of means 0.2, 95% CI 0.1, 0.7).
Fewer participants seroconverted to the wild-type strains than 
to the homologous JE-CV vaccine strain with the exception of 
genotype I strain 1991 TVP-8236. The lowest seroconversion 
rates were against virus strain JKT 9092/TVP-6265 particularly 
by participants in co-administration/placebo group (Fig. 3).
All participants seroconverted to YF vaccine and retained 
neutralizing titers (PRNT
50
 ≥1:20) at month six (Table 2 and 
Fig. 4). One participant in the co-administration/placebo group 
showed evidence of neutralizing antibodies to YFV before receiv-
ing YF vaccine at day 30 and demonstrated a four-rise in titer 
following immunization.
The neutralizing GMTs for anti-YFV antibody are shown in 
Figure 4. There was no significant difference between anti-YFV 
antibody GMTs when YF vaccine was administered 30 days 
before or after JE vaccine (ratio of means 1.1, 95% CI 0.5, 2.6) or 
when co-administered with JE vaccine (ratio of means 0.6, 95% 
CI 0.1, 0.7).
Table 2. percent of participants in the pp population seroconverting (pRNT50 ≥1:20 or 4-fold rise from baseline) to Je-cV or YF-17D at day 30 or day 60 
after first immunization
JE/YF group YF/JE group
Co-administration group
JE + YF on Day 0 JE + YF on Day 30
(n = 17) (n = 23) (n = 13) (n = 10)
JE-CV seroconversion, n (%)
Day 30 17 (100) 2 (9) 12 (92) 0 (0)
Day 60 17 (100) 21 (91) 12 (92) 10 (100)
30 days post JE-CV 
(95% cI)
17 (100) 
(81, 100)
21 (91) 
(72, 99)
22 (96) 
(78, 100)
YF-17D seroconversion, (n)%
Day 30 0 (0) 23 (100) 13 (100) 1 (10)
Day 60 17 (100) 23 (100) 13 (100) 10 (100)
30 days post YF-17D 
(95% cI)
17 (100) 
(81, 100)
23 (100) 
(85, 100)
23 (100) 
(85, 100)
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Figure 2. Geometric mean anti-Je-cV neutralizing antibody titer in the pp vaccinees following immunization with either Je, YF or both Je and YF co-
administered together at day 0. Ratio of means for Group 3 (co-ad total)/Group 1 (Je followed by YF) at day 30 = 0.2 (95% cI 0.1, 0.7). Ratio of means for 
Group 2 (YF followed by Je)/Group 1 (Je followed by YF) at day 30 = 0.3 (95% cI 0.1, 0.9). a significant difference between treatment groups (p < 0.05) 
occurs when the geometric means does not contain the value 1.
porcine gelatin, while Stamaril® contains approximately 3–4 log
10
 
PFU of YF-17D virus and has no animal derived stabilizers. The 
formulations of YF vaccines used and the handling after reconsti-
tution as well as YF vaccination histories of participants enrolled 
in each study may account for these differences.
Anti-JE-CV antibody titers were higher in participants who 
were immunized first with JE vaccine than in those who received 
YF vaccine first or when the vaccines were co-administered. 
Monath et al.11,12 previously showed that immunization with YF 
vaccine at least nine months before inoculation with JE-CV did 
not interfere with viremia or antibody responses. JE-CV shares 
the non-structural genes of YF-17D virus so it is possible that 
recently acquired cytotoxic immunity to the shared non-struc-
tural proteins of the YFV (anti-viral vector immunity) inhibited 
the replication of the JE-CV virus and the development of anti-
JEV antibody titers following JE vaccine administration 30 days 
after YF vaccine. Although replication kinetics were not specifi-
cally assessed in this study, a reduced antigenic mass of replicating 
JE-CV compared to YF-17D may have reduced the anti-JE-CV 
GMTs in the co-administration group. JE-CV has been reported 
to cause lower levels of viremia in primates and humans11,14 than 
YF vaccine, hence JE-CV may have been “out-competed” by the 
faster replication of YF vaccine when both vaccines were admin-
istered together.
Antibody responses against the JE vaccine strain were higher 
than the wild type strains (with the exception of JEV strain 
1991 TVP-8236). Reduced in vitro cross-neutralizing responses 
to heterologous JEV genotypes have been observed with inac-
tivated mouse-brain derived JE vaccines and was attributed to 
local strain variation and to original antigenic sin.15 Despite these 
laboratory observations, vaccines derived from a limited number 
of JEV strains (Beijing, Nakayama and SA14) appear to protect 
against clinical infections with other strains of JEV.6,8,16 JE-CV 
is derived from the SA14-14-2 vaccine10 which has been shown 
to be protective in pre-licensing studies in the Peoples Republic 
of China17 and immunization of children with a single dose of 
SA14-14-2 is associated with long-term protection.18-20 Recently, 
Beasley et al.21 also demonstrated passive cross-protection by 
anti-JE-CV antibodies against a panel of wild-type strains from 
the four JEV genotypes in an in vivo mouse model.
Participants and Methods
The study was conducted at a single site (Q-Pharm) in Queensland, 
Australia from July 2004 to April 2005. After screening, partici-
pants were randomized by the unblinded study pharmacist to six 
treatment groups according to a randomization schedule with a 
block size of six prepared by an independent statistician. To assess 
specific local reactions, JE and YF vaccines were administered 
in separate arms by the blinded Investigators. No participant 
was made aware of their treatment but blinding efficacy was not 
assessed. Participants returned to the clinic on days 15, 30, 45, 
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Participants were healthy, flavivirus-naïve, volunteers, aged 
18–55 years, in good general health without a clinically signifi-
cant medical history, physical examination or laboratory find-
ing at screening. Participants were required to provide written 
informed consent. Female participants were neither pregnant nor 
breast-feeding and were required to use effective contraception 
from at least one month prior to the study to one month after 
the study (day 60). Participants were excluded from the study 
if they had a history of flavivirus infection or immunization 
(based on participant responses and a review of medical records), 
impaired immunity, a history of serious adverse reactions to prior 
vaccines or chicken eggs, transfusion of blood or blood products 
within six months of the screening visit or during treatment, or 
administration of another vaccine within 28 days of study immu-
nization. They also were excluded for fever (body temperature 
>38.1°C) or acute illness within three days of planned immuni-
zation. Other exclusion criteria included intention to travel out 
of the area during the treatment period, antibodies to hepati-
tis C virus and human immunodeficiency virus or hepatitis B 
virus surface antigen in the screening blood sample, lactation or 
intended pregnancy, excessive alcohol consumption, drug abuse 
60 and six months after their first injection (day 0). Safety assess-
ments were made by the Investigators and blood samples taken 
for antibody analysis at all visits, including day 0.
Vaccines. JE-CV is a pilot liquid formulation prepared by cul-
turing the JE-CV virus in Vero cells (vaccine lot number 00C02; 
1.3 x 106 PFU/mL; Acambis Inc., now part of Sanofi Pasteur).10,11 
Yellow fever vaccine (Stamaril®, batch X-5426-5 Sanofi Pasteur, 
Marcy L’Etoile, France) contained not less than 1,000 mouse 
lethal dose endpoint 50% units as a lyophilized powder. Both vac-
cines were diluted or re-constituted using 0.9% saline for injec-
tion and administered in a volume of 0.5 mL within 60 minutes of 
reconstitution. Placebo was sterile saline for injection. Participants 
received either 3.8 log
10
 PFU of JE vaccine, 1,000 mouse LD
50
 
units of YF vaccine, or placebo as a subcutaneous injection into 
the upper deltoid, i.e., each participant received a total of four 
injections (two of placebo and one each of JE and YF vaccine), 
two at each visit (one in each arm). The blinded, double-dummy 
syringes were prepared by an unblinded study pharmacist and 
provided to the Investigators for injection with the syringe barrels 
blinded with colored tape. The study pharmacist did not reveal 
the blind to the Investigators and had no other role in the study.
Figure 3. percent of participants in the pp population seroconverting (pRNT50 ≥ 1:20 or 4-fold rise from baseline) to Je-cV and wild-type JeV strains, 30 
days after last immunization with either Je, YF or both Je and YF co-administered together at day 0.
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Figure 4. Geometric mean anti-YF-17D neutralizing antibody titer in the pp vaccinees following immunization with either Je, YF or both Je and YF co-
administered together at day 0. Ratio of means for Group 3 (co-ad total)/Group 1 (Je followed by YF) at day 30 = 0.6 (95% cI 0.3, 1.2). Ratio of means for 
Group 2 (YF followed by Je)/Group 1 (Je followed by YF) at day 30 = 1.1 (95% cI 0.5, 2.6). a significant difference between treatment groups (p < 0.05) 
occurs when the geometric means does not contain the value 1.
or significant psychiatric illness or a history of damage to the 
blood brain barrier.
The protocol and informed consent forms were reviewed by 
the Australian Defence Human Research Ethics Committee 
(# 345/03) and the Queensland Institute of Medical Research 
Human Research Ethics Committee (# P753). The study was 
conducted in accord with Good Clinical Practice and local 
regulatory approvals included a clinical trial exemption (# 
99/2/4014), dealing not involving release licence (071/2002) 
and review by the Gene and Related Therapies Advisory Panel 
(#04-01).
Safety evaluation. The primary safety outcome evaluated 
AE incidence rates at day 30 following the first vaccine adminis-
tered. Safety assessments were based on physical examination and 
routine laboratory testing (hematology and biochemistry) with 
urinalysis performed at the site by dipstick with abnormal uri-
nalysis results confirmed at the laboratory. Adverse events were 
observed, reported or elicited by interview and coded using the 
Medical Dictionary for Regulatory Activities (MedDRA) version 
7.1 (Maintenance and Support Services Organization, Chantilly, 
VA, USA). The incidence of all AEs and treatment emergent AEs 
considered related to the study drug (i.e., Investigator rated pos-
sibly, probably or definitely related) were recorded for each treat-
ment group based on subject interview with diary cards used as 
an aide memoire. Severity of reactions was deemed mild (aware 
of sign/symptom but easily tolerated), moderate (discomfort to 
cause interference with usual activity) or severe (incapacitating 
with inability to work or perform usual activity). Local injection 
site reactions and rash was deemed mild (<2 cm or rash restricted 
to <18% body surface), moderate (>2 cm or rash equivalent to an 
area >18%) and severe (>6 cm or rash equivalent to an area >half 
the body).
Serological tests. Serum was stored at -70 ± 5°C and all sam-
ples were tested in parallel. For the determination of PRNT, test 
samples were heat inactivated and three ten-fold serial dilutions 
were prepared in duplicate. They were mixed with a fixed amount 
of virus, incubated for one hour at 37°C and plated on LLC-MK2 
cells in six well plates. Titers are determined as described by 
Russel et al.22 Sera were tested by a single technician. All samples 
from a single time point were tested on the same day. A positive 
control was used throughout the tests to ensure consistency of 
the results. Participants who were seronegative at baseline (<1:10 
titer) required a PRNT
50
 titer of ≥1:20 to meet the criteria for 
seroconversion. Any PRNT
50
 value reported as “<LOQ” was con-
verted to “LOQ/2”, where LOQ was the lower limit of quantifi-
cation, defined as 10 for this study. Any PRNT
50
 value reported 
as “>ULQ” was converted to “2ULQ”, where “ULQ” was the 
upper limit of quantification.
Immunogenicity. The primary immunogenicity outcome 
was the proportion of flavivirus naïve participants that sero-
converted to JE or YF vaccines after immunization. Secondary 
immunogenicity outcomes were GMT against JE-CV, YF-17D 
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Conclusion
The results suggest that JE-CV and YF-17D vaccines are safe and 
immunogenic when administered sequentially, in either order, 
one month apart or when administered concurrently.
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and wild-type JEV strains (genotype I, 1991 TVP-8236; geno-
type II, B1034/8; genotype III, Beijing; genotype IV, JKT 9092/
TVP-6265), which were calculated by taking log
10
 transforma-
tion of the observed titer for each participant and calculation of 
the arithmetic mean.
Statistical methods. Statistical methods examined a two 
sided non-directional test of the hypothesis with significance set 
at 5%. The study was not powered to show statistically signifi-
cant treatment differences and the immunogenicity comparisons 
in this study are considered exploratory. A sample of 36 partici-
pants per group at 95% CI was selected to detect very common 
AEs (frequency ≥10%) in the safety population (using the rules 
of threes for calculation of sample size) with the assumption 
that up to 10% of participants would withdraw. The popula-
tion employed to assess safety consisted of all participants who 
received at least one injection of vaccine or placebo (108 par-
ticipants). The intent to treat (ITT) population consisted of 
the safety population who had provided day 0 (baseline) and 
post-immunization (day 30) blood samples for antibody analysis 
(108 participants). The PP population included the ITT popu-
lation who were flavivirus naïve at day 0 (PRNT
50
 <1:10) and 
who were compliant with the protocol throughout the trial (63 
participants).
Descriptive summaries were made for the proportion of par-
ticipants seroconverting to each vaccine. Confidence intervals for 
GMTs were calculated as exponent {mean ± t
df; 0.025
 se} where se 
is the standard error of the mean of log
10
 titer and t
df; 0.025
 is the 
upper 2.5% of the t-distribution with degrees of freedom (df), 
n-1. Analysis of variance (treatment only) for the log
10
 titers of 
the three groups was performed with differences in means and 
the 95% CI calculated. Back transformation of these values gave 
an estimate of the ratio of mean GMTs and the associated 95% 
CI. The ratio of GMT was considered statistically significant if 
the CI did not contain the value one.
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